FUSEN PHARM(01652): Henan Fusen obtained an additional capital injection of 300 million yuan.

FUSEN PHARM (01652) announced that on June 18, 2026, investors (Nanyang Chan Tou and Henan Xisheng), Nanyang Hengsheng, Wealth Depot (HK), and the target company Henan Fushen have entered into a capital increase agreement. The investors are required to make a total cash investment of RMB 300 million to subscribe to the target company's newly increased registered capital, representing approximately 34% of the total expanded registered capital of the target company after the capital increase. Upon completion of the capital increase, the company will indirectly hold approximately 66% of the total expanded registered capital of the target company, with the target company remaining a subsidiary of the company. The Board of Directors believes that the capital increase is in the overall interest of the company and its shareholders. The capital injection will provide additional funds to Henan Fushen, enabling it to repay certain debts and strengthen its working capital. This is expected to enhance the financial resilience of Henan Fushen, and subsequently that of the group, especially during a period when the operating environment is challenging and there is ongoing pressure on liquidity and working capital. In addition, the introduction of investors with a Chinese state-owned background can provide strategic and financing support to the group, as well as additional resources and market reputation for the development and optimization of the group's operations.